Scientists develop robust iPSC-derived rejuvenated T lymphocytes for cervical cancer treatment

FHS
March 6, 2024
3:03 am

Cervical cancer is among the most common malignancies affecting women worldwide. In 2020 alone, approximately 600,000 women were diagnosed with this disease, and over 314,000 died from it.

With a promising new Keytruda contender, Summit prepares to spar with Merck

CHICAGO — Summit Therapeutics is prepared to take on the world’s best-selling drug. On Thursday, the biotech’s stock nearly tripled after reporting that its cancer

June 3, 2024

Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer

Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for a type of blood cancer — a concession that competition

January 4, 2024

Poor Neighborhood, More Than Race, Predicts Greater Lupus Skin Severity

People with discoid lupus erythematosus (DLE) living in areas marked by poverty tended to have more severe manifestations, a study in Philadelphia found, whereas associations

July 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.